Corvus Pharmaceuticals (CRVS) Price & Analysis

Compare

674 Followers

CRVS Stock Chart & Stats

$17.53

-$0.10(-1.74%)

At close: Jan 08 4:00 PM EST

$17.53

-$0.10(-1.74%)

Day’s Range― - ―

52-Week Range$2.54 - $26.95

Previous CloseN/A

Volume202.27K

Average Volume (3M)5.45M

Market Cap

$1.47B

Enterprise Value$1.49B

Total Cash (Recent Filing)$65.69M

Total Debt (Recent Filing)$1.01M

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Mar 05, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding83,767,650

10 Day Avg. Volume1,263,940

30 Day Avg. Volume5,452,169

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)10.02

Price to Sales (P/S)0.00

P/FCF Ratio-12.83

Enterprise Value/Market Cap1.02

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-38.92

Forecast

1Y Price Target

$31.80

Price Target Upside81.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.58

Revenue Forecast (FY)$1.50M

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 1 expansion cohort demonstrated a clear separation versus placebo in refractory atopic dermatitis, indicating potential meaningful benefit for patients who failed prior biologic and JAK inhibitor therapies.

Development And Commercial OutlookFinalized Phase 2 design and planned initiation in early 2026, together with multiple major clinical readouts slated for 2026, supports upside to market penetration and valuation if trials meet endpoints.

Safety And TolerabilitySoquelitinib showed a safety profile comparable to placebo in treated patients, reducing concerns about adverse events that could hinder regulatory review or adoption.

Bears Say

Commercial And Partnership ExecutionCommercial, partnership, and execution challenges could limit market access and slow adoption, putting downward pressure on the stock if planned collaborations do not materialize.

Financial PositionNo reported product revenues leaves the company reliant on external financing and partnership deals to fund development, increasing dilution and execution risk for investors.

Intellectual Property RiskIntellectual property disputes or weak patent coverage could erode competitive barriers and reduce long-term revenue potential even in the event of favorable clinical outcomes.

Corvus Pharmaceuticals News

Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings

Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:1. Implied volatility suggests the...

8h ago

CRVS

CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Corvus Pharmaceuticals Inc. (CRVS) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates, Wall Street...

2d ago

CRVS

3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

CRVS

NRIX

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $30 from $20 and...

1M ago

CRVS

Mizuho biotech analysts hold an analyst/industry conference call

Biotech Analysts, along with Dr. Brian Lester, a leading dermatologist, participates in an Analyst/Industry conference call entitled, “Recent...

1M ago

APGE

CRVS

Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering

Corvus Pharmaceuticals ( ($CRVS) ) has provided an update. On January 21, 2026, Corvus Pharmaceuticals entered into an...

1M ago

CRVS

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

Jefferies analyst Roger Song raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $42 from $13 and...

1M ago

CRVS

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

The deal size was increased to $175M in common stock from $150M in common stock. Jefferies and Goldman...

1M ago

CRVS

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $32 from $15 and keeps an Outperform...

1M ago

CRVS

Closing Bell Movers: Netflix down 5% after soft guidance

The return from long weekend saw the markets getting rattled as President Trump’s proposed tariffs starting at 10%...

1M ago

HWC

OZK

Corvus Pharmaceuticals Suspends At-The-Market Equity Program

Corvus Pharmaceuticals ( ($CRVS) ) just unveiled an update. On January 20, 2026, Corvus Pharmaceuticals, Inc. suspended, in...

1M ago

CRVS

Corvus Pharmaceuticals announces $150M common stock offering

Corvus Pharmaceuticals (CRVS) announced that it has commenced an underwritten public offering of $150M of shares of its...

1M ago

CRVS

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

Barclays raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $28 from $16 and keeps an Overweight...

1M ago

CRVS

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $20 from $13 and keeps an Outperform...

1M ago

CRVS

CRVS FAQ

What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?

Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $26.95 in the past 12 months.

What is Corvus Pharmaceuticals Inc’s market cap?

Corvus Pharmaceuticals Inc’s market cap is $1.47B.

When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?

Corvus Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2026 which is today.

How were Corvus Pharmaceuticals Inc’s earnings last quarter?

Currently, no data Available

Is Corvus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corvus Pharmaceuticals Inc pay dividends?

Corvus Pharmaceuticals Inc does not currently pay dividends.

What is Corvus Pharmaceuticals Inc’s EPS estimate?

Corvus Pharmaceuticals Inc’s EPS estimate is -0.13.

How many shares outstanding does Corvus Pharmaceuticals Inc have?

Corvus Pharmaceuticals Inc has 83,767,650 shares outstanding.

What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in CRVS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Corvus Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-35.82%

Trailing 12-Months

Asset Growth

36.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals (CRVS) Earnings & Revenues

Historic Earnings Reports

CRVS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented significant positive developments, including a notable reduction in net loss, a strong cash position, and successful clinical trial progress for soquelitinib. However, increased R&D expenses and delays in trial result reporting were challenges. Overall, the positive aspects, particularly related to clinical advancements and financial improvements, seem to outweigh the negatives.View all CRVS earnings summaries

CRVS Stock 12 Month Forecast

Average Price Target

$31.80

▲(81.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","43":"$43","12.25":"$12.25","22.5":"$22.5","32.75":"$32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,12.25,22.5,32.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.98,22.596923076923076,24.213846153846156,25.83076923076923,27.447692307692307,29.064615384615387,30.681538461538462,32.29846153846154,33.91538461538462,35.5323076923077,37.14923076923077,38.76615384615384,40.38307692307693,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.98,21.812307692307694,22.644615384615385,23.47692307692308,24.30923076923077,25.141538461538463,25.973846153846154,26.806153846153848,27.638461538461538,28.470769230769232,29.303076923076922,30.135384615384616,30.96769230769231,{"y":31.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.98,21.443076923076923,21.906153846153845,22.369230769230768,22.832307692307694,23.295384615384616,23.75846153846154,24.22153846153846,24.684615384615384,25.14769230769231,25.61076923076923,26.073846153846155,26.536923076923078,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.25,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >